PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21472003-0	2011	Phenethyl isothiocyanate exhibits antileukemic activity in vitro and in vivo by inactivation of Akt and activation of JNK pathways.	phenethyl isothiocyanate	0-24	mitogen-activated protein kinase 8	Homo sapiens	118-121	
21472003-5	2011	Conversely, enforced activation of Akt by a constitutively active Akt construct markedly abrogated PEITC-mediated JNK activation, Mcl-1 downregulation, caspase activation, and apoptosis, and also interruption of the JNK pathway by pharmacological or genetically (e.g., siRNA) attenuated PEITC-induced apoptosis.	phenethyl isothiocyanate	99-104	mitogen-activated protein kinase 8	Homo sapiens	114-117	
21472003-5	2011	Conversely, enforced activation of Akt by a constitutively active Akt construct markedly abrogated PEITC-mediated JNK activation, Mcl-1 downregulation, caspase activation, and apoptosis, and also interruption of the JNK pathway by pharmacological or genetically (e.g., siRNA) attenuated PEITC-induced apoptosis.	phenethyl isothiocyanate	99-104	mitogen-activated protein kinase 8	Homo sapiens	216-219	
21472003-6	2011	Finally, administration of PEITC markedly inhibited tumor growth and induced apoptosis in U937 xenograft model in association with inactivation of Akt, activation of JNK, as well as downregulation of Mcl-1.	phenethyl isothiocyanate	27-32	mitogen-activated protein kinase 8	Homo sapiens	166-169	
21472003-7	2011	Taken together, these findings represent a novel mechanism by which agents targeting Akt/JNK/Mcl-1 pathway potentiate PEITC lethality in transformed and primary human leukemia cells and inhibitory activity of tumor growth of U937 xenograft model.	phenethyl isothiocyanate	118-123	mitogen-activated protein kinase 8	Homo sapiens	89-92